The new "triple agonist" weight loss medication called retatrutide can help people lose an average of 28.7 percent of ...
In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
The futures are trading lower after what started as a bounce-back Monday turned into a reversal Monday, as the AI/Datacenter rotation trade continues to gather steam during the last whole trading week ...
Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...
Treatment with Kisunla was associated with sustained clinical benefits, specifically less symptom worsening and significant amyloid clearance up to 3 years, in early symptomatic Alzheimer’s disease, ...
The Brown County Community Foundation is pleased to announce the recipient of the 2026 Lilly Endowment Community Scholarship ...
Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.
U.S. lawsuits against Novo Nordisk and Eli Lilly alleging patients taking weight loss drugs lost some or all of their ...
Zacks Investment Research on MSN
Eli Lilly or Merck: Where should investors put their money?
Eli Lilly LLY and Merck MRK are both major global pharmaceutical companies with blockbuster drug portfolios and deep ...
There is no exact known number of GLP-1 patients who say their say their sense of taste has changed since starting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback